Vimarsana
Biggest News Aggregation in the World

Page 2 - Oncologic Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncologic Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncologic Sciences Today - Breaking & Trending Today

Dr Eroglu on Future Steps for Assessing Ceritinib Plus Trametinib in Metastatic Melanoma - Vimarsana News

Dr Eroglu on Future Steps for Assessing Ceritinib Plus Trametinib in Metastatic Melanoma

Zeynep Eroglu, MD, discusses future steps for assessing ceritinib in combination with trametinib in patients with metastatic melanoma.

Merit Medical Receives FDA 510(k) Clearance for SCOUT MD Surgical Guidance System - Vimarsana News

Merit Medical Receives FDA 510(k) Clearance for SCOUT MD Surgical Guidance System

SOUTH JORDAN - Merit Medical Systems, Inc. , a global leader of healthcare technology, has received US Food and Drug Administration 501 clearance for the SCOUT MD Surgical Guidance System. The...

Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System - Vimarsana News

Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has ...

Merit Medical Receives FDA 510(k) Clearance for SCOUT MD Surgical Guidance System - Vimarsana News

Merit Medical Receives FDA 510(k) Clearance for SCOUT MD Surgical Guidance System

New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries

Dr Komrokji on Ongoing Investigations With Luspatercept in MDS - Vimarsana News

Dr Komrokji on Ongoing Investigations With Luspatercept in MDS

Rami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.